Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

作者：Eggemann Holm^*; Ignatov Atanas; Smith Bobbie J; Altmann Udo; von Minckwitz Gunter; Roehl Freidrich W; Jahn Mark; Costa Serban Dan

来源：Breast Cancer Research and Treatment, 2013, 137(2): 465-470.

DOI：10.1007/s10549-012-2355-3

• Male breast cancer
• Tamoxifen
• Aromatase inhibitor
• Adjuvant treatment

To determine the impact of adjuvant treatment with tamoxifen and aromatase inhibitors (AI) on the survival of men with breast cancer. We analyzed 257 male patients with hormone-receptor-positive breast cancer from numerous German population-based cancer registries treated with tamoxifen (N = 207) or aromatase inhibitors (N = 50). The median follow-up was 42.2 (range 2-115) months. Median age at diagnosis was 68 (range 36-91) years. Thirty-seven (17.9 %) patients treated with tamoxifen and 16 (32.0 %) patients treated with AI died (log rank p = 0.007). After the adjustment for the patient%26apos;s age, tumor size, node status, and tumor grading, the AI treatment was linked to a 1.5-fold increase in risk of mortality compared to tamoxifen (HR 1.55; 95 % CI: 1.13-2.13; p = 0.007). The overall survival in male breast cancer was significantly better after adjuvant treatment with tamoxifen compared to an aromatase inhibitor. Tamoxifen should be considered as the treatment of choice for hormone-receptor-positive male breast cancer.

• 出版日期2013-1